Abstract
The sympathetic nervous system has moved towards center stage in cardiovascular medicine. The importance of the sympathetic activation in heart failure and in renal insufficiency progression and mortality is indeed now well established. In essential hypertension evidence has been provided that this may be the case, because sympathetic overactivity is a key factor in the pathophysiology of the disease, thereby promoting not only the blood pressure increase but also the development and progression of the hypertension-related cardiovascular and metabolic complications, such as left ventricular hypertrophy, vascular hypertrophy, endothelial dysfunction, cardiac rhythm disturbances and insulin resistance. In this review article the main pathophysiologic and mechanistic features of the sympathetic overactivity characterizing the essential hypertensive state will be examined. This will be followed by an analysis of the effects of 1) the hyperadrenergic state on the cardiovascular risk profile as well as on the end organ damage and 2) the different antihypertensive compounds on sympathetic and baroreflex function. The rationale for obtaining during antihypertensive drug treatment an effective sympathoinhibition will be finally highlighted.
Keywords: sympathetic activity, arterial baroreflex, end organ damage, insulin resistance, antihypertensive agents, antihypertensive treatment
Current Pharmaceutical Design
Title: Sympathetic and Baroreflex Function in Hypertension: Implications for Current and New Drugs
Volume: 10 Issue: 29
Author(s): Guido Grassi
Affiliation:
Keywords: sympathetic activity, arterial baroreflex, end organ damage, insulin resistance, antihypertensive agents, antihypertensive treatment
Abstract: The sympathetic nervous system has moved towards center stage in cardiovascular medicine. The importance of the sympathetic activation in heart failure and in renal insufficiency progression and mortality is indeed now well established. In essential hypertension evidence has been provided that this may be the case, because sympathetic overactivity is a key factor in the pathophysiology of the disease, thereby promoting not only the blood pressure increase but also the development and progression of the hypertension-related cardiovascular and metabolic complications, such as left ventricular hypertrophy, vascular hypertrophy, endothelial dysfunction, cardiac rhythm disturbances and insulin resistance. In this review article the main pathophysiologic and mechanistic features of the sympathetic overactivity characterizing the essential hypertensive state will be examined. This will be followed by an analysis of the effects of 1) the hyperadrenergic state on the cardiovascular risk profile as well as on the end organ damage and 2) the different antihypertensive compounds on sympathetic and baroreflex function. The rationale for obtaining during antihypertensive drug treatment an effective sympathoinhibition will be finally highlighted.
Export Options
About this article
Cite this article as:
Grassi Guido, Sympathetic and Baroreflex Function in Hypertension: Implications for Current and New Drugs, Current Pharmaceutical Design 2004; 10 (29) . https://dx.doi.org/10.2174/1381612043382756
DOI https://dx.doi.org/10.2174/1381612043382756 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Blood Pressure Variability and Mortality in end Stage Renal Disease
Current Hypertension Reviews Genetic Basis of Ureterocele
Current Genomics Vascular Effects of Estrogenic Menopausal Hormone Therapy
Reviews on Recent Clinical Trials The Roles of β-Carotene in Cardiomyocytes
Current Nutrition & Food Science Editorial [Hot Topic:Metalloproteinases Revisited (Guest Editor: Marcia L. Moss)]
Current Pharmaceutical Biotechnology Non-Invasive Assessment of Atherosclerosis Risk
Current Drug Targets - Cardiovascular & Hematological Disorders Systematic Review of Public Education and Policy for Stroke Prevention
Current Drug Targets An Association between MicroRNA-21 Expression and Vitamin D Deficiency in Coronary Artery Disease
MicroRNA Aging and DNA Methylation
Current Chemical Biology Heart Failure in the Middle East
Current Cardiology Reviews Neurocognitive Monitoring and Care During Pediatric Cardiopulmonary Bypass — Current and Future Directions
Current Cardiology Reviews Role of Cardiovascular Aldosterone in Hypertension
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Cardiovascular Risk in Psoriasis: Current State of the Art
Current Vascular Pharmacology Lipases in Medicine: An Overview
Mini-Reviews in Medicinal Chemistry Targeting Tumor Angiogenesis in Gastrointestinal Malignancies
Current Angiogenesis (Discontinued) Early Hematoma Enlargement in Primary Intracerebral Hemorrhage
Current Drug Targets Effect of Simvastatin on Inflammatory Cytokines Balance in Air Pouch Granuloma Model
Inflammation & Allergy - Drug Targets (Discontinued) Astrocytes: From the Physiology to the Disease
Current Alzheimer Research Pharmacophoric Modeling and Atom-Based 3D-QSAR of Novel 1-Aryl-3-(1-acylpiperidin-4-yl) Urea as Human Soluble Epoxide Hydrolase Inhibitors (sEHIs)
Medicinal Chemistry MEET THE GUEST EDITOR
Combinatorial Chemistry & High Throughput Screening